A Phase II Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options.
Every 4 weeks untill disease progression
Yes
E-mail: ClinicalTrials@ ImClone.com
Study Chair
ImClone LLC
United States: Food and Drug Administration
CA225-041
NCT00055419
February 2003
August 2004
Name | Location |
---|---|
ImClone Investigational Site | Denver, Colorado 80262 |
ImClone Investigational Site | Greenwich, Connecticut 06830 |
ImClone Investigational Site | New York, New York 10021 |
ImClone Investigational Site | St. Charles, Missouri 63301 |
ImClone Investigational Site | Bakersfield, California 93309 |
ImClone Investigational Site | Washington, District of Columbia 20057 |
ImClone Investigational Site | Jacksonville, Florida 32207 |
ImClone Investigational Site | Atlanta, Georgia 30318 |
ImClone Investigational Site | Decatur, Illinois 62526 |
ImClone Investigational Site | Louisville, Kentucky 40202 |
ImClone Investigational Site | New Orleans, Louisiana 70121 |
ImClone Investigational Site | Baltimore, Maryland 21204 |
ImClone Investigational Site | Ypsilanti, Michigan 48198 |
ImClone Investigational Site | Minneapolis, Minnesota 55416 |
ImClone Investigational Site | Great Falls, Montana 59405 |
ImClone Investigational Site | Las Vegas, Nevada 89109 |
ImClone Investigational Site | Voorhees, New Jersey 08043 |
ImClone Investigational Site | Cleveland, Ohio 44134 |
ImClone Investigational Site | Portland, Oregon 97239 |
ImClone Investigational Site | Greenville, South Carolina 29605 |
ImClone Investigational Site | Memphis, Tennessee 38104 |
ImClone Investigational Site | Dallas, Texas 75230 |
ImClone Investigational Site | Norfolk, Virginia 23502 |
ImClone Investigational Site | Green Bay, Wisconsin 54307 |